Biotech Analysts Schimmer & Zhou, along with CEO David Kim, CFO Uneek Mehra and CMO Robert Kim discuss the Company’s wet AMD gene therapy Phase 2 PRISM Trial on a conference call to be held on January 22 at 10:30 am hosted by Cantor Fitzgerald. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FDMT:
- 4D Molecular appoints Kasahara as Chief Scientific Officer of 4DMT
- 4D Molecular provides pipeline progress, near-term milestones
- 4D Molecular, Arbor Biotechnologies establish partnership to co-develop
- 4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
- 4D Molecular receives FDA RMAT designation for 4D-150
